Search Results

Genetown

CENTOGENE Announces Adoption of All Resolutions Tabled at 2024 Annual General Meeting

CENTOGENE N.V., the essential life science partner for data-driven answers in rare and neurodegenerative diseases, announced the voting results of the Company’s 2024 Annual General Meeting.

May 31, 2024

·

4 min read

Genetown

CENTOGENE Biodatabank Grows to Incorporate Disease Insights From Over 850,000 Diverse Patients

Centogene N.V., the essential life science partner for data-driven answers in rare and neurodegenerative diseases, revealed significant growth in the CENTOGENE Biodatabank, the world’s largest real-world data repository for rare and neurodegenerative diseases.

May 10, 2024

·

6 min read

BioMidwest

C-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development

Critical Path Institute and Centogene N.V. are pleased to announce the signing of a Memorandum of Understanding to advance drug development for lysosomal diseases and improve the quality of life for those impacted by these conditions.

June 20, 2024

·

5 min read

Genetown

CENTOGENE and Evotec Discover Promising New Molecule to Treat Gaucher Disease

Centogene N.V. today announced the discovery of a new small molecule together with Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO).

May 14, 2024

·

9 min read

Press Releases

CENTOGENE Receives Delisting Notice From Nasdaq

August 8, 2024

·

5 min read

Genetown

CENTOGENE Secures Approx. $20 Million to Strengthen Cash PositionExpanding Relationship With Lifera, a Biopharma Company Owned by the PIF

Centogene N.V. announced it has entered into a set of agreements with Lifera, a biopharmaceutical company wholly-owned by the Public Investment Fund in Saudi Arabia.

May 15, 2024

·

5 min read

Business

CENTOGENE Reports Full Year 2023 Financial Results and Recent Business Highlights

Centogene N.V. (Nasdaq: CNTG) (“we” or the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced financial results for the fiscal year ended December 31, 2023, and provided a business update.

May 15, 2024

·

19 min read

Press Releases

CENTOGENE Data on Novel Genetic Risk Factor for Parkinson’s Disease in The Lancet Neurology

September 26, 2024

·

5 min read

Genetown

CENTOGENE Explores Strategic Alternatives

Centogene N.V., the essential life science partner for data-driven answers in rare and neurodegenerative diseases, announced that the Company has decided to explore a range of strategic alternatives focused on sustainable long-term value creation for the benefit of its stakeholders.

February 28, 2024

·

5 min read

Genetown

CENTOGENE Receives French Research Tax Credit Accreditation

Centogene N.V. announced that it has been recognized by the French Ministry of Higher Education and Research as a qualified organization to support partners conducting R&D projects in France.

January 24, 2024

·

4 min read